Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Extended Cleavage Specificities of Rabbit and Guinea Pig Mast Cell Chymases: Two Highly Specific Leu-Ases.

Zhongwei Y, Akula S, Fu Z, de Garavilla L, Kervinen J, Thorpe M, Hellman L.

Int J Mol Sci. 2019 Dec 16;20(24). pii: E6340. doi: 10.3390/ijms20246340.

2.

Extended cleavage specificities of mast cell proteases 1 and 2 from golden hamster: Classical chymase and an elastolytic protease comparable to rat and mouse MCP-5.

Thorpe M, Fu Z, Albat E, Akula S, de Garavilla L, Kervinen J, Hellman L.

PLoS One. 2018 Dec 6;13(12):e0207826. doi: 10.1371/journal.pone.0207826. eCollection 2018.

3.

Extended cleavage specificity of sheep mast cell protease-2: A classical chymase with preference to aromatic P1 substrate residues.

Fu Z, Akula S, Thorpe M, Chahal G, de Garavilla L, Kervinen J, Hellman L.

Dev Comp Immunol. 2019 Mar;92:160-169. doi: 10.1016/j.dci.2018.11.019. Epub 2018 Nov 24.

PMID:
30481523
4.

Extended cleavage specificity of human neutrophil cathepsin G: A low activity protease with dual chymase and tryptase-type specificities.

Thorpe M, Fu Z, Chahal G, Akula S, Kervinen J, de Garavilla L, Hellman L.

PLoS One. 2018 Apr 13;13(4):e0195077. doi: 10.1371/journal.pone.0195077. eCollection 2018.

5.

Highly Selective Cleavage of Cytokines and Chemokines by the Human Mast Cell Chymase and Neutrophil Cathepsin G.

Fu Z, Thorpe M, Alemayehu R, Roy A, Kervinen J, de Garavilla L, Ã…brink M, Hellman L.

J Immunol. 2017 Feb 15;198(4):1474-1483. doi: 10.4049/jimmunol.1601223. Epub 2017 Jan 4.

6.

Enhanced vascular chymase-dependent conversion of endothelin in the diabetic kidney.

Harrison-Bernard LM, de Garavilla L, Bivona BJ.

Ochsner J. 2013 Spring;13(1):49-55.

7.

Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature.

Park S, Bivona BJ, Ford SM Jr, Xu S, Kobori H, de Garavilla L, Harrison-Bernard LM.

Hypertension. 2013 Feb;61(2):465-71. doi: 10.1161/HYPERTENSIONAHA.111.202424. Epub 2012 Dec 3.

8.

The role of the epithelium in chronic inflammatory airway disease.

Dudas PL, de Garavilla L, Lundblad LK, Knight DA.

Pulm Pharmacol Ther. 2012 Dec;25(6):413-4. doi: 10.1016/j.pupt.2012.10.005. No abstract available.

PMID:
23182086
9.

Potency variation of small-molecule chymase inhibitors across species.

Kervinen J, Crysler C, Bayoumy S, Abad MC, Spurlino J, Deckman I, Greco MN, Maryanoff BE, de Garavilla L.

Biochem Pharmacol. 2010 Oct 1;80(7):1033-41. doi: 10.1016/j.bcp.2010.06.014. Epub 2010 Jun 23.

PMID:
20599788
10.

Thrombin and trypsin directly activate vagal C-fibres in mouse lung via protease-activated receptor-1.

Kwong K, Nassenstein C, de Garavilla L, Meeker S, Undem BJ.

J Physiol. 2010 Apr 1;588(Pt 7):1171-7. doi: 10.1113/jphysiol.2009.181669. Epub 2010 Feb 8.

11.

Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa.

Giardino EC, Haertlein BJ, de Garavilla L, Costanzo MJ, Damiano BP, Andrade-Gordon P, Maryanoff BE.

Blood Coagul Fibrinolysis. 2010 Mar;21(2):128-34. doi: 10.1097/MBC.0b013e3283358100.

PMID:
20010091
12.

Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation.

Maryanoff BE, de Garavilla L, Greco MN, Haertlein BJ, Wells GI, Andrade-Gordon P, Abraham WM.

Am J Respir Crit Care Med. 2010 Feb 1;181(3):247-53. doi: 10.1164/rccm.200904-0627OC. Epub 2009 Oct 29.

PMID:
19875688
13.

Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease.

Belkowski SM, Boot JD, Mascelli MA, Diamant Z, de Garavilla L, Hertzog B, Polkovitch D, Towers M, Batheja A, D'Andrea MR.

Clin Exp Allergy. 2009 Aug;39(8):1179-86. doi: 10.1111/j.1365-2222.2009.03247.x. Epub 2009 Apr 7.

PMID:
19400896
14.

Cleaved SLPI, a novel biomarker of chymase activity.

Belkowski SM, Masucci J, Mahan A, Kervinen J, Olson M, de Garavilla L, D'Andrea MR.

Biol Chem. 2008 Sep;389(9):1219-24. doi: 10.1515/BC.2008.138.

PMID:
18713008
15.

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.

Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.

Eur J Pharmacol. 2008 Aug 20;590(1-3):333-42. doi: 10.1016/j.ejphar.2008.06.010. Epub 2008 Jun 7.

PMID:
18599033
16.

Introduction to the pulmonary research group's symposium upper airway disease: clinical and research perspectives.

Corboz MR, Phillips JE, de Garavilla L.

Pulm Pharmacol Ther. 2008;21(3):431-2. doi: 10.1016/j.pupt.2008.02.004. Epub 2008 Feb 26. No abstract available.

PMID:
18342560
17.

Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.

Costanzo MJ, Yabut SC, Zhang HC, White KB, de Garavilla L, Wang Y, Minor LK, Tounge BA, Barnakov AN, Lewandowski F, Milligan C, Spurlino JC, Abraham WM, Boswell-Smith V, Page CP, Maryanoff BE.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2114-21. doi: 10.1016/j.bmcl.2008.01.093. Epub 2008 Jan 30.

PMID:
18272363
18.

Structural basis for elastolytic substrate specificity in rodent alpha-chymases.

Kervinen J, Abad M, Crysler C, Kolpak M, Mahan AD, Masucci JA, Bayoumy S, Cummings MD, Yao X, Olson M, de Garavilla L, Kuo L, Deckman I, Spurlino J.

J Biol Chem. 2008 Jan 4;283(1):427-36. Epub 2007 Oct 31.

19.

Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.

Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, de Garavilla L, Hall J, Minor LK, Wang Y, Corcoran TW, Di Cera E, Cantwell AM, Savvides SN, Damiano BP, Maryanoff BE.

J Med Chem. 2007 Apr 19;50(8):1727-30. Epub 2007 Mar 16.

PMID:
17361995
20.

Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.

Gunnet JW, Matthews JM, Maryanoff BE, de Garavilla L, Andrade-Gordon P, Damiano B, Hageman W, Look R, Stahle P, Streeter AJ, Wines PG, Demarest KT.

Clin Exp Pharmacol Physiol. 2006 Apr;33(4):320-6.

PMID:
16620295
21.

Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent.

Lawson EC, Santulli RJ, Dyatkin AB, Ballentine SA, Abraham WM, Rudman S, Page CP, de Garavilla L, Damiano BP, Kinney WA, Maryanoff BE.

Bioorg Med Chem. 2006 Jun 15;14(12):4208-16. Epub 2006 Feb 21.

PMID:
16495061
22.

Adenosine A1 antagonism attenuates beta-adrenergic-resistant sudden hypoxic cardiac insufficiency.

Gao E, Kaplan JL, Victain MS, Dalsey WC, de Garavilla L.

Acad Emerg Med. 2005 May;12(5):389-95.

23.

In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.

Costanzo MJ, Almond HR Jr, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE.

J Med Chem. 2005 Mar 24;48(6):1984-2008. Erratum in: J Med Chem. 2007 Nov 15;50(23):5868.

PMID:
15771442
24.

A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.

de Garavilla L, Greco MN, Sukumar N, Chen ZW, Pineda AO, Mathews FS, Di Cera E, Giardino EC, Wells GI, Haertlein BJ, Kauffman JA, Corcoran TW, Derian CK, Eckardt AJ, Damiano BP, Andrade-Gordon P, Maryanoff BE.

J Biol Chem. 2005 May 6;280(18):18001-7. Epub 2005 Feb 28.

25.

Mer receptor tyrosine kinase signaling participates in platelet function.

Chen C, Li Q, Darrow AL, Wang Y, Derian CK, Yang J, de Garavilla L, Andrade-Gordon P, Damiano BP.

Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1118-23. Epub 2004 May 6.

PMID:
15130911
26.

Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.

Matthews JM, Hoekstra WJ, Dyatkin AB, Hecker LR, Hlasta DJ, Poulter BL, Andrade-Gordon P, de Garavilla L, Demarest KT, Ericson E, Gunnet JW, Hageman W, Look R, Moore JB, Reynolds CH, Maryanoff BE.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2747-52.

PMID:
15125926
27.

Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.

Dyatkin AB, Hoekstra WJ, Kinney WA, Kontoyianni M, Santulli RJ, Kimball ES, Fisher MC, Prouty SM, Abraham WM, de Garavilla L, Andrade-Gordon P, Hlasta DJ, He W, Hornby PJ, Damiano BP, Maryanoff BE.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):591-6. Erratum in: Bioorg Med Chem Lett. 2004 May 3;14(9):2371.

PMID:
14741249
28.

Adenosine A1 antagonism attenuates atropine-resistant hypoxic bradycardia in rats.

Kaplan JL, Gao E, De Garavilla L, Victain M, Minczak B, Dalsey WC.

Acad Emerg Med. 2003 Sep;10(9):923-30.

29.

Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.

Costanzo MJ, Yabut SC, Almond HR Jr, Andrade-Gordon P, Corcoran TW, De Garavilla L, Kauffman JA, Abraham WM, Recacha R, Chattopadhyay D, Maryanoff BE.

J Med Chem. 2003 Aug 28;46(18):3865-76.

PMID:
12930148
30.

Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney.

Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, de Garavilla L, Li PL, Zou AP.

Am J Physiol Renal Physiol. 2003 Oct;285(4):F792-8. Epub 2003 Jun 3.

31.

Dextrose is absorbed by rectum in hypoglycemic rats.

McGee D, Chen A, de Garavilla L.

J Emerg Med. 2003 Apr;24(3):253-7.

PMID:
12676292
32.

Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists.

Matthews JM, Greco MN, Hecker LR, Hoekstra WJ, Andrade-Gordon P, de Garavilla L, Demarest KT, Ericson E, Gunnet JW, Hageman W, Look R, Moore JB, Maryanoff BE.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):753-6.

PMID:
12639574
33.

Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.

Dyatkin AB, Hoekstra WJ, Hlasta DJ, Andrade-Gordon P, de Garavilla L, Demarest KT, Gunnet JW, Hageman W, Look R, Maryanoff BE.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3081-4. Erratum in: Bioorg Med Chem Lett. 2004 Jun 21;14(12):3363.

PMID:
12372506
34.

Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model.

Kinney WA, Almond HR Jr, Qi J, Smith CE, Santulli RJ, de Garavilla L, Andrade-Gordon P, Cho DS, Everson AM, Feinstein MA, Leung PA, Maryanoff BE.

Angew Chem Int Ed Engl. 2002 Aug 16;41(16):2940-4. No abstract available.

PMID:
12203418
35.

Nonpeptide inhibitors of cathepsin G: optimization of a novel beta-ketophosphonic acid lead by structure-based drug design.

Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, Corcoran TW, de Garavilla L, Kauffman JA, Recacha R, Chattopadhyay D, Andrade-Gordon P, Maryanoff BE.

J Am Chem Soc. 2002 Apr 17;124(15):3810-1.

PMID:
11942800
36.

Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.

Damiano BP, Mitchell JA, Giardino E, Corcoran T, Haertlein BJ, de Garavilla L, Kauffman JA, Hoekstra WJ, Maryanoff BE, Andrade-Gordon P.

Thromb Res. 2001 Oct 15;104(2):113-26.

PMID:
11672755
37.

Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism.

de Garavilla L, Vergnolle N, Young SH, Ennes H, Steinhoff M, Ossovskaya VS, D'Andrea MR, Mayer EA, Wallace JL, Hollenberg MD, Andrade-Gordon P, Bunnett NW.

Br J Pharmacol. 2001 Aug;133(7):975-87.

38.

Adenosine A1 receptor antagonist prolongs survival in the hypoxic rat.

Gao E, Kaplan JL, Shi Y, Victain M, Dalsey WC, de Garavilla L.

J Cardiovasc Pharmacol. 2001 Sep;38(3):384-94.

PMID:
11486243
39.

Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.

Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung Wm, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF.

J Pharmacol Exp Ther. 2001 Jul;298(1):34-42.

PMID:
11408522
40.

Prediction of hyperkalemia in dogs from electrocardiographic parameters using an artificial neural network.

Porter RS, Kaplan J, Zhao N, de Garavilla L, Eynon CA, Wenger FG, Dalsey WC.

Acad Emerg Med. 2001 Jun;8(6):599-603.

41.

Hypertonic saline treatment of severe hyperkalemia in nonnephrectomized dogs.

Kaplan JL, Eynon CA, Dalsey WC, Braitman LE, Clas D, De Garavilla L.

Acad Emerg Med. 2000 Sep;7(9):965-73.

42.

Antagonism of the cardiodepressant effects of adenosine during acute hypoxia.

Cummings J, Kaplan JL, Gao E, Clas D, Dalsey WC, de Garavilla L.

Acad Emerg Med. 2000 Jun;7(6):618-24.

43.

Exercise in the heat: effects of an adenosine antagonist.

Durkot MJ, de Garavilla L.

Int J Sports Med. 2000 May;21(4):270-4.

PMID:
10853698
44.

Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery.

Damiano BP, D'Andrea MR, de Garavilla L, Cheung WM, Andrade-Gordon P.

Thromb Haemost. 1999 May;81(5):808-14.

PMID:
10365757
45.

Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1.

Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, de Garavilla L, Andrade-Gordon P.

J Pharmacol Exp Ther. 1999 Feb;288(2):671-8.

PMID:
9918574
46.

Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5.

Silver PJ, Pagani ED, Dundore RL, de Garavilla L, Bode DC, Bacon ER.

Eur J Pharmacol. 1998 May 22;349(2-3):263-8.

PMID:
9671106
47.

Use of tube condensation as an indicator of endotracheal tube placement.

Kelly JJ, Eynon CA, Kaplan JL, de Garavilla L, Dalsey WC.

Ann Emerg Med. 1998 May;31(5):575-8.

PMID:
9581141
48.

Adenosine antagonists and cardiopulmonary resuscitation.

de Garavilla L.

Acad Emerg Med. 1996 Nov;3(11):1075-6. No abstract available.

49.

Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.

De Garavilla L, Pagani ED, Buchholz RA, Dundore R, Bode DC, Volberg ML, Jackson KN, Pratt P, Silver PJ.

Eur J Pharmacol. 1996 Oct 10;313(1-2):89-96.

PMID:
8905333
50.

In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors.

Sawutz DG, Bode DC, Briggs GM, Reid JR, Canniff P, Caldwell L, Faltynek CR, Miller D, Dunn JA, de Garavilla L, Guiles JW, Weigelt C, Michne W, Treasurywala AM, Silver PJ.

Biochem Pharmacol. 1996 Jun 28;51(12):1631-8.

PMID:
8687478

Supplemental Content

Loading ...
Support Center